300 episodes

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

The Readout Loud STAT

    • Business
    • 4.6 • 285 Ratings

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

    298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard

    298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard

    Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver disease.

    • 35 min
    297: VC turmoil, GLP-1 competition, & the war on recovery

    297: VC turmoil, GLP-1 competition, & the war on recovery

    For the entirety of the opioid overdose epidemic, the U.S. has had readily available tools that are proven to save lives. STAT’s Lev Facher joins us to explain his reporting on why virtually every sector of American society is standing in the way of their use. We also discuss the latest news in the life sciences, including the haves and have-nots of venture capital, and the race to develop effective oral treatments for obesity.

    • 27 min
    296: Legal insider trading, booming biotech stocks, & the next GLP-1

    296: Legal insider trading, booming biotech stocks, & the next GLP-1

    We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it's such a good idea. We also discuss a banner month for biotech stocks and the latest twist in obesity research.
    Here's where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner workings) of the U.S. health care industry, Health Care Inc.

    • 24 min
    295: Humira’s legacy, CEO symbolism, and genomic surgery

    295: Humira’s legacy, CEO symbolism, and genomic surgery

    First, former Alnylam Pharmaceuticals CEO John Maraganore and STAT’s Matthew Herper join us to discuss the legacy of AbbVie chief executive Richard Gonzalez, who announced his retirement this week. Then, we dive into the fascinating world of fetal genome surgery, as STAT’s Megan Molteni joins us to explain the work of a scientist named Tippi MacKenzie.
    Here's where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner workings) of the U.S. health care industry, Health Care Inc.

    • 34 min
    294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking

    294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking

    The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry’s struggle to make headway — and how it factors into the 2024 election. We also discuss the latest news in the life sciences, including a twist in the future of Alnylam Pharmaceuticals, competition to Vertex Pharmaceuticals’ pain drug, and Gilead Sciences' latest acquisition.
    Here's where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner workings) of the U.S. health care industry, Health Care Inc.

    • 30 min
    293: AI in medicine, detangling hype, and Icelandic DNA

    293: AI in medicine, detangling hype, and Icelandic DNA

    It's our all-AI episode. First, STAT’s Casey Ross joins us to explain his reporting on how researchers and pharmaceutical firms are using the technology to find new drug targets, design therapies, and improve clinical trials. Then, we talk to Joel Dudley, a partner at the venture firm Innovation Endeavors, about how to discern promising ideas from wastes of time when it comes to AI in biotech.
    Here's where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner workings) of the U.S. health care industry, Health Care Inc.

    • 32 min

Customer Reviews

4.6 out of 5
285 Ratings

285 Ratings

C4l71n ,

Great Podcast

Amazing content — the podcast hosts really understand the biopharma field (both the science and history) and their jokes are also quite funny.

WndyG ,

Good but could be better

This podcast does a good job of tackling developments in Biotech and boiling down complex subjects into cliff notes versions for listeners who want to get a quick overview of what is happening in the industry. The hosts are smart and entertaining but can be overly judgmental and “know-it-alls” in their commentary. After all, they are reporting on brilliant innovation and amazing science, not actually creating brilliant innovation and amazing science.

Two gluon ,

Hosts have technical knowledge but could benefit from journalism or communications courses

I want to dive deeper into the pharma market, and this podcast helps get there maybe 65% of the way.

My issue is that some (not all) of the hosts can be very inarticulate. Sometimes there’s a lot of stuttering or awkward pauses as they communicate their thoughts. It can come across as them being unprepared — which maybe is the format?

Top Podcasts In Business

The Ramsey Show
Ramsey Network
Money Rehab with Nicole Lapin
Money News Network
NerdWallet's Smart Money Podcast
NerdWallet Personal Finance
The Diary Of A CEO with Steven Bartlett
DOAC
Planet Money
NPR
The Money Mondays
Dan Fleyshman

You Might Also Like

Business Of Biotech
Matt Pillar
Raising Health
Andreessen Horowitz
BioCentury This Week
BioCentury
The Long Run with Luke Timmerman
Timmerman Report
Biotech Hangout
Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more
Biotech 2050 Podcast
Biotech 2050